We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abcam Plc | LSE:ABC | London | Ordinary Share | GB00B6774699 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,226.00 | 1,240.00 | 1,246.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/11/2014 20:25 | Now shipped 140k products in last 90 days, up from 130k - probably explains today's rise. | trident5 | |
21/11/2014 10:53 | Chart starting to turn up, director changes, directors buying. Setting up for a rally here? CR | cockneyrebel | |
03/11/2014 10:27 | ABCAM Plc AGM Statement Alert TIDMABC RNS Number : 8840V ABCAM Plc 03 November 2014 For immediate release 3 November 2014 ABCAM PLC ("Abcam" or "the Company") AGM Statement Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, is holding its Annual General Meeting this morning. At the meeting Michael Redmond, Abcam's outgoing Chairman, will make the following statement: "As previously announced, trading in the 2014/15 financial year has started well. The positive momentum we saw in the second half of our last financial year is continuing, as we invest in new products and capabilities, and increase our geographic penetration. The Board believes that Abcam is well positioned to deliver continued growth and to meet its financial and strategic objectives for the year." | ranger101 | |
27/8/2014 10:17 | I have a small holding in SRT, will increase on order news. Luck apad | apad | |
27/8/2014 09:08 | My largest is more speculative APAD - it's SRT. Revenue wise it's still a bit blue sky/jam tomorrow, but it looks positioned to be the global market leader if AIS takes off. | trident5 | |
27/8/2014 08:55 | ABC just overhauled by TRCS trid. so 2nd as well. This must be an omen:-) What's your largest? apad | apad | |
26/8/2014 21:38 | That's a coincidence Apad - Kentz was my 2nd biggest holding too. Now Abcam is. I hope this does half as well as Kentz. | trident5 | |
26/8/2014 21:10 | Now my biggest holding since KENZ got taken out, rich. 1 May 2014: 131276 antibodies, last 90 days 13000 products to 83 countries, 26 vacancies 1 July 2014: 133073 antibodies, last 90 days 13000 products to 89 countries, 34 vacancies 21 Aug 2014: 134552 antibodies, last 90 days 13000 products to 89 countries, 39 vacancies apad | apad | |
26/8/2014 20:42 | Chart doesn't look too bad.... | richscotsman | |
19/8/2014 13:46 | That's the kiss of death, then. | trident5 | |
19/8/2014 13:19 | G.Sachs start coverage today with a buy. Results early Sep CR | cockneyrebel | |
12/8/2014 23:09 | Good to see continuous improvement to help reduce overheads and grow market share.... CAMBRIDGE, England--(BUSINESS WIRE)--Abcam plc, a global leader in the supply of innovative protein research tools, announced today it has established a direct service to Australia and New Zealand. The move signifies the importance of this region and Abcam's focus on providing the best products and services to accelerate the pace of researchers' scientific discoveries. The new service enables customers in Australia and New Zealand to order their research tools directly from Abcam rather than through a distributor. These customers will also benefit from direct technical support, and delivery times reduced by up to 50% from order to delivery. | richscotsman | |
24/7/2014 16:26 | happy days... decent profit growth with currency movement and double digit when that it stripped out. China sales whilst still very small could start to contribute more strongly in the next few years as well. Apad - we both increased too soon but not too late! Rich | richscotsman | |
23/7/2014 08:55 | that's good - the question is, will we break through 400 (and stay there)? | artibee | |
23/7/2014 08:52 | Tempus column in The Times today has a good piece on ABCAM rating them a Buy as shares have fallen a long way and recovery looks set with 10.6% growth in second-half revenues. | rvsy38 | |
18/7/2014 08:21 | I guess government spending + currencies + increased spending on headcount, rich. I increased too soon. apad | apad | |
14/7/2014 23:00 | Trading update soon.... There are headwinds re currencies but I hope this has been written down too much... A week or two and we should be a bit more informed.... | richscotsman | |
02/7/2014 14:10 | Lots of new jobs in the states.... Bodes well.... | richscotsman | |
01/7/2014 08:18 | 1 May 2014: 131276 antibodies, last 90 days 130000 products to 83 countries, 26 vacancies 1 July 2014: 133073 antibodies, last 90 days 130000 products to 89 countries, 34 vacancies apad | apad | |
20/5/2014 18:35 | Thanks simon... I am going to start loading up my sipp at this price! | richscotsman | |
20/5/2014 07:56 | Unicorn AIM VCT - 20/5/14 Abcam (-23%) is a global leader in the supply of innovative protein research tools. In March 2014, Abcam released its financial results for the six month period ended 31 December 2013, which were in line with your Investment Manager's internal forecasts. Revenues of £61.9m (H2 2012: £57.3m) represented half-year on half-year growth of over 8%, while earnings per share were up 6.5% to 8.74p (H2 2012: 8.21p). Abcam remains a cash generative business with a robust balance sheet. Net cash balances at the period end amounted to £35.3m. Despite Abcam's many obvious qualities, market reaction to the release of Interim Results in early March was negative as investors worried about currency headwinds and the impact of possible cuts to health budgets in the key North American market, which accounts for 43% of total sales. As a result, Abcam's share price ended the period markedly lower. The holding has been retained in the portfolio in the expectation that the de-rating in the value of Abcam will prove to be temporary. | simon gordon | |
06/5/2014 20:33 | It's kind of bowly and sitting at the bottom of an egg, that pointy bit pointing downwards - is that the beak? | trident5 | |
06/5/2014 20:06 | Next leg up starting? Nice bowly sort of chart imo. | cockneyrebel | |
06/5/2014 20:02 | Chart looks okay... Struggling against string dollar but slowly and surely we are coming back to the long term trend... | richscotsman | |
02/5/2014 08:10 | Looking strong today. | scrabble1975 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions